Moleculin Biotech grants director 4,000 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Moleculin Biotech, Inc. (MBRX) director Robert E. George received 4,000 stock options on November 17, 2026, in connection with his Board of Directors service; the options have an exercise price of $6.83 per share. They vest on the earlier of November 17, 2027, or the date of the Company's next annual meeting of shareholders, subject to the grantee's continued service on the Company's Board of Directors on the vesting date. The reported option position after the grant was 4,334 options; the options expire November 17, 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) F2, F1 | 4,000 | -- | -- |
Footnotes (2)
- F1. The options set forth in this table vest on the earlier of November 17, 2027 or the date of the Company's next annual meeting of shareholders, subject to the grantee's continued service on the Company's Board of Directors on the vesting date.
- F2. The options were issued in connection with the reporting person's Board of Director service to the Company.
Key Figures
Key Terms
vest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did MBRX director Robert E. George receive?
What is the exercise price of Robert E. George's MBRX options?
When do MBRX director Robert E. George's options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.